Annual report pursuant to Section 13 and 15(d)

Note 21 - Segments - Segment Information (Details)

v3.8.0.1
Note 21 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Tc 99m tilmanocept sales revenue $ 9,000 $ 18,000 $ 4,000 $ 9,000 $ 39,601 $ 19,075
Tc99m tilmanocept license revenue 100,000 1,296,000 246,000 254,000 100,000 1,795,625 1,133,333
Tc99m tilmanocept royalty revenue 9,000         9,126
Grant and other revenue 386,000 224,000 512,000 580,000 1,022,000 511,000 917,000 686,000 1,701,311 3,136,408 1,860,953
Revenues                 1,810,437 4,971,634 3,013,361
Cost of goods sold                 3,651 62,260 3,226
Research and Development Expense                 4,513,842 7,138,080 10,562,729
Selling, general and administrative expenses, excluding depreciation and amortization (a) [1]                 10,929,785 7,466,487 10,365,950
Depreciation, Depletion and Amortization, Nonproduction [2]                 240,166 453,549 522,196
Loss from operations (c) (3,521,000) (2,385,000) (4,823,000) (3,148,000) (3,240,000) (910,000) (2,241,000) (3,758,000) (13,877,007) [3] (10,148,742) [3] (18,440,740) [3]
Other income (expense) (d)                 (3,912,679) [4] 2,770,848 (4,603,857)
Benefit from income taxes 201,000 776,000 1,631,000 1,454,000         4,062,489
Loss from continuing operations (6,170,000) (1,541,000) (3,152,000) (2,865,000) (2,118,000) (1,761,000) (817,000) (2,682,000) (13,727,197) (7,377,894) (23,044,597)
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax                 89,163,811
Net income (loss)                 74,945,856 (14,309,031) (27,563,535)
Total assets, net of depreciation and amortization 20,781,436       12,461,676       20,781,436 12,461,676  
Capital expenditures                 33,690 1,847 39,001
Cost of goods sold, excluding depreciation and amortization                   62,260 3,226
Other income (expense), excluding equity in the loss of R-NAV, LLC (d) [4]                   2,786,007 (4,298,604)
Income (Loss) from Equity Method Investments                 (15,159) (305,253)
Loss from continuing operations                   (7,377,894) (23,044,597)
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax 2,112,000 $ 151,000 $ (2,036,000) $ 88,446,000 (1,764,000) $ 1,702,000 $ (5,865,000) $ (1,004,000) (490,758) (6,931,137) (4,518,938) [5]
UNITED STATES                      
Tc 99m tilmanocept sales revenue                
Total assets, net of depreciation and amortization 20,749,109       12,329,143       20,749,109 12,329,143 14,552,834
Non-US [Member]                      
Tc 99m tilmanocept sales revenue                 39,601 19,075
Total assets, net of depreciation and amortization 32,327       132,533       32,327 132,533 411,679
Diagnostics Segment [Member]                      
Tc99m tilmanocept license revenue                 100,000 1,795,625 1,133,333
Tc99m tilmanocept royalty revenue                 9,126    
Grant and other revenue                 1,506,232 3,011,642 1,860,953
Revenues                 1,615,358 4,846,868 3,013,361
Cost of goods sold                 3,651    
Research and Development Expense                 3,784,255 6,375,929 9,831,834
Selling, general and administrative expenses, excluding depreciation and amortization (a) [1]                
Depreciation, Depletion and Amortization, Nonproduction [2]                 56,317 232,091
Loss from operations (c) [3]                 (2,172,548) (1,647,638) (7,053,790)
Other income (expense) (d) [4]                    
Benefit from income taxes                 496,127    
Loss from continuing operations                 (1,676,421)    
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax                 88,673,053    
Net income (loss)                 86,996,632 (8,578,775) (12,767,388)
Capital expenditures                 26,589
Cost of goods sold, excluding depreciation and amortization                   62,260 3,226
Other income (expense), excluding equity in the loss of R-NAV, LLC (d) [4]                  
Income (Loss) from Equity Method Investments                  
Loss from continuing operations                   (1,647,638) (7,053,790)
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax                   (6,931,137) (5,713,598) [5]
Diagnostics Segment [Member] | UNITED STATES                      
Tc 99m tilmanocept sales revenue                
Total assets, net of depreciation and amortization 13,065,871       3,815,271       13,065,871 3,815,271 4,161,029
Diagnostics Segment [Member] | Non-US [Member]                      
Tc 99m tilmanocept sales revenue                 39,601 19,075
Total assets, net of depreciation and amortization 30,476       131,752       30,476 131,752 410,666
Therapeutics Segment [Member]                      
Tc99m tilmanocept license revenue                
Tc99m tilmanocept royalty revenue                    
Grant and other revenue                 195,079 124,766
Revenues                 195,079 124,766
Cost of goods sold                    
Research and Development Expense                 729,587 762,151 730,895
Selling, general and administrative expenses, excluding depreciation and amortization (a) [1]                 34,484 63,158 123,884
Depreciation, Depletion and Amortization, Nonproduction [2]                
Loss from operations (c) [3]                 (568,992) (700,543) (854,779)
Other income (expense) (d) [4]                    
Benefit from income taxes                 129,936    
Loss from continuing operations                 (439,056)    
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax                    
Net income (loss)                 (439,056) (700,543) (854,779)
Capital expenditures                
Cost of goods sold, excluding depreciation and amortization                  
Other income (expense), excluding equity in the loss of R-NAV, LLC (d) [4]                  
Income (Loss) from Equity Method Investments                  
Loss from continuing operations                   (700,543) (854,779)
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax                   [5]
Therapeutics Segment [Member] | UNITED STATES                      
Tc 99m tilmanocept sales revenue                
Total assets, net of depreciation and amortization 49,001       15,075       49,001 15,075
Therapeutics Segment [Member] | Non-US [Member]                      
Tc 99m tilmanocept sales revenue                
Total assets, net of depreciation and amortization            
Corporate Segment [Member]                      
Tc99m tilmanocept license revenue                
Tc99m tilmanocept royalty revenue                    
Grant and other revenue                
Revenues                
Cost of goods sold                    
Research and Development Expense                
Selling, general and administrative expenses, excluding depreciation and amortization (a) [1]                 10,895,301 7,403,329 10,242,066
Depreciation, Depletion and Amortization, Nonproduction [2]                 240,166 397,232 290,105
Loss from operations (c) [3]                 (11,135,467) (7,800,561) (10,532,171)
Other income (expense) (d) [4]                 (3,912,679)    
Benefit from income taxes                 3,436,426    
Loss from continuing operations                 (11,611,720)    
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax                    
Net income (loss)                 (11,611,720) (5,029,713) (13,941,368)
Capital expenditures                 33,690 1,847 12,412
Cost of goods sold, excluding depreciation and amortization                  
Other income (expense), excluding equity in the loss of R-NAV, LLC (d) [4]                   2,786,007 (4,298,604)
Income (Loss) from Equity Method Investments                   (15,159) (305,253)
Loss from continuing operations                   (5,029,713) (15,136,028)
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax                   1,194,660 [5]
Corporate Segment [Member] | UNITED STATES                      
Tc 99m tilmanocept sales revenue                
Total assets, net of depreciation and amortization 7,634,237       8,498,797       7,634,237 8,498,797 10,391,805
Corporate Segment [Member] | Non-US [Member]                      
Tc 99m tilmanocept sales revenue                
Total assets, net of depreciation and amortization $ 1,851       $ 781       $ 1,851 $ 781 $ 1,013
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments. Marketing and selling expenses are allocated to our individual reportable segments.
[2] Depreciation and amortization is reflected in research and development ($0, $0 and $10,617 for the years ended December 31, 2017, 2016 and 2015, respectively), and selling, general and administrative expenses ($240,166, $397,232 and $460,839 for the years ended December 31, 2017, 2016 and 2015, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
[4] Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.
[5] Amount not allocated to a reportable segment represents contingent consideration recognized related to 2015 GDS Business revenue royalties pursuant to the 2011 sale of the GDS Business to Devicor, net of tax effect. See Note 1(a).